US64132R2067 - Common Stock
0.5493 0 (-0.11%)
NEUROBO PHARMACEUTICALS INC
NASDAQ:NRBO (6/2/2023, 12:29:48 PM)
0.5493
0 (-0.11%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-08-05. The firm is focused primarily on therapies for cardiometabolic diseases. Its therapeutics programs include DA-1241 and DA-1726. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist. OXM is a naturally occurring, 37-amino acid peptide hormone that is released from the gut after ingestion of a meal, activating both the GLP-1 and glucagon receptors, prompting reduced food intake as well as an increase in energy expenditure, potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists. Each of DA-1241 and DA-1726 is being developed for the treatment of nonalcoholic steatohepatitis.
NEUROBO PHARMACEUTICALS INC
200 Berkeley St., Fl 19
Boston MASSACHUSETTS 02116
P: 18577029600.0
CEO: Richard Kang
Employees: 4
Website: https://www.neurobopharma.com/
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today...
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today...
The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning!
Here you can normally see the latest stock twits on NRBO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: